{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:16:02Z","timestamp":1793740562019,"version":"4.6.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jaccao.2023.12.006","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:58:51Z","timestamp":1708437531000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Cardiac Troponin in Patients With Light\u00a0Chain and Transthyretin Cardiac\u00a0Amyloidosis"],"prefix":"10.1016","volume":"6","author":[{"given":"Laura","family":"De Michieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Iliceto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan S.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"11","key":"10.1016\/j.jaccao.2023.12.006_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.jaccao.2023.12.006_bib3","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jaccao.2023.12.006_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.jaccao.2023.12.006_bib6","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jaccao.2023.12.006_bib7","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/eurheartj\/ehq251","article-title":"Recommendations for the use of cardiac troponin measurement in acute cardiac care","volume":"31","author":"Thygesen","year":"2010","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jaccao.2023.12.006_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1515\/CCLM.2009.322","article-title":"Genetic and biochemical heterogeneity of cardiac troponins: clinical and laboratory implications","volume":"47","author":"Lippi","year":"2009","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jaccao.2023.12.006_bib10","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/CIRCULATIONAHA.121.058489","article-title":"Skeletal muscle disorders: a noncardiac source of cardiac troponin T","volume":"145","author":"du Fay de Lavallaz","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/clinchem\/hvaa204","article-title":"Sex-specific 99th percentile URLs for cardiac troponin assays\u2014their time has come","volume":"67","author":"Lobo","year":"2021","journal-title":"Clin Chem"},{"issue":"4-5","key":"10.1016\/j.jaccao.2023.12.006_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clinbiochem.2014.08.021","article-title":"IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays","volume":"48","author":"Apple","year":"2015","journal-title":"Clin Biochem"},{"issue":"9","key":"10.1016\/j.jaccao.2023.12.006_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jacc.2018.12.046","article-title":"Recommendations for institutions transitioning to high-sensitivity troponin testing","volume":"73","author":"Januzzi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib14","article-title":"High-sensitivity cardiac troponin t compared with standard troponin T testing on emergency department admission: how much does it add in everyday clinical practice?","volume":"2","author":"Hammerer-Lercher","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1373\/clinchem.2011.166165","article-title":"Counterpoint: standardization of cardiac troponin I assays will not occur in my lifetime","volume":"58","author":"Apple","year":"2012","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/CCM.0B013E318164E2E4","article-title":"Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients","volume":"36","author":"Babuin","year":"2008","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.jaccao.2023.12.006_bib17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/clinchem\/hvab062","article-title":"High-sensitivity cardiac troponin T for the detection of myocardial injury and risk stratification in COVID-19","volume":"67","author":"De Michieli","year":"2021","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.jaccao.2023.12.006_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jacc.2012.12.026","article-title":"Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease","volume":"61","author":"Omland","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.amjmed.2015.12.009","article-title":"Prognostic impact of myocardial injury related to various cardiac and noncardiac conditions","volume":"129","author":"Sarkisian","year":"2016","journal-title":"Am J Med"},{"issue":"25","key":"10.1016\/j.jaccao.2023.12.006_bib20","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.10.020","article-title":"High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease","volume":"68","author":"Ford","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jaccao.2023.12.006_bib21","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/j.jacc.2021.04.050","article-title":"Clinical impact of high-sensitivity cardiac troponin T implementation in the community","volume":"77","author":"Ola","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jaccao.2023.12.006_bib22","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/CIRCULATIONAHA.119.042866","article-title":"High-sensitivity troponin and the application of risk stratification thresholds in patients with suspected acute coronary syndrome","volume":"140","author":"Bularga","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jaccao.2023.12.006_bib23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jacc.2018.06.051","article-title":"Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease","volume":"72","author":"Adamson","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jaccao.2023.12.006_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0002-9149(01)01877-X","article-title":"Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation","volume":"88","author":"Miller","year":"2001","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"10.1016\/j.jaccao.2023.12.006_bib26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jaccao.2023.12.006_bib27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.jaccao.2023.12.006_bib28","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38\u03b1 MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jaccao.2023.12.006_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jmb.2019.12.015","article-title":"Inherent biophysical properties modulate the toxicity of soluble amyloidogenic light chains","volume":"432","author":"Maritan","year":"2020","journal-title":"J\u00a0Mol Biol"},{"issue":"38","key":"10.1016\/j.jaccao.2023.12.006_bib30","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1074\/jbc.M116.736736","article-title":"Cell damage in light chain amyloidosis","volume":"291","author":"Marin-Argany","year":"2016","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib31","first-page":"1274","article-title":"The role of light kappa and\u00a0lambda chains in heart function assessment in\u00a0patients with AL amyloidosis","volume":"10","author":"Czy\u017cewska","year":"2021","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.jaccao.2023.12.006_bib32","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jaccao.2023.12.006_bib33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.jaccao.2023.12.006_bib34","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","article-title":"Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"107","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib35","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral","year":"2015","journal-title":"Biosci Rep"},{"issue":"13","key":"10.1016\/j.jaccao.2023.12.006_bib36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/hemato3010005","article-title":"Mechanisms of organ damage and novel treatment targets in AL amyloidosis","volume":"3","author":"Lavatelli","year":"2022","journal-title":"Hemato"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.hfc.2011.03.009","article-title":"Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment","volume":"7","author":"Seldin","year":"2011","journal-title":"Heart Fail Clin"},{"issue":"2","key":"10.1016\/j.jaccao.2023.12.006_bib39","article-title":"Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis","volume":"2","author":"Tanaka","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jaccao.2023.12.006_bib40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9440(10)62244-4","article-title":"Cellular response of cardiac fibroblasts to amyloidogenic light chains","volume":"166","author":"Trinkaus-Randall","year":"2005","journal-title":"Am J Pathol"},{"issue":"20","key":"10.1016\/j.jaccao.2023.12.006_bib42","article-title":"Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis","volume":"10","author":"Pucci","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jaccao.2023.12.006_bib43","article-title":"Correlation between cardiac images, biomarkers, and amyloid load in wild-type transthyretin amyloid cardiomyopathy","volume":"11","author":"Morioka","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jaccao.2023.12.006_bib44","first-page":"358","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib45","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/his.12793","article-title":"Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases","volume":"68","author":"Larsen","year":"2016","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.jaccao.2023.12.006_bib46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.7326\/0003-4819-131-11-199912070-00007","article-title":"Systemic amyloidosis presenting with angina pectoris","volume":"131","author":"Al Suwaidi","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.echo.2017.09.007","article-title":"Abnormal coronary flow velocity reserve and decreased myocardial contractile reserve are main factors in relation to physical exercise capacity in cardiac amyloidosis","volume":"31","author":"Clemmensen","year":"2018","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"2","key":"10.1016\/j.jaccao.2023.12.006_bib48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13506129.2016.1176020","article-title":"Abnormal stress echocardiography findings in cardiac amyloidosis","volume":"23","author":"Ong","year":"2016","journal-title":"Amyloid"},{"issue":"7","key":"10.1016\/j.jaccao.2023.12.006_bib49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacc.2013.03.065","article-title":"Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure","volume":"62","author":"Takashio","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jaccao.2023.12.006_bib50","doi-asserted-by":"crossref","first-page":"1287.e1","DOI":"10.1016\/j.amjmed.2005.06.017","article-title":"Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis","volume":"118","author":"Neben-Wittich","year":"2005","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9343(00)00471-X","article-title":"Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis","volume":"109","author":"Mueller","year":"2000","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa325","article-title":"Cardiac amyloidosis mimicking acute coronary syndrome: a case report and literature review","volume":"4","author":"Nguyen","year":"2020","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506129.2011.571319","article-title":"Myocardial infarction with \u201cclean coronaries\u201d caused by amyloid light-chain AL amyloidosis: a case report and literature review","volume":"18","author":"Tsai","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2023.12.006_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131204","article-title":"Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance","volume":"389","author":"De Michieli","year":"2023","journal-title":"Int J Cardiol"},{"issue":"14","key":"10.1016\/j.jaccao.2023.12.006_bib55","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jaccao.2023.12.006_bib56","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1016\/j.jacc.2018.04.029","article-title":"Troponin release and reversible left ventricular dysfunction after transient pressure overload","volume":"71","author":"Weil","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib57","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11886-010-0101-1","article-title":"Myocardial ischemia in patients with diastolic dysfunction and heart failure","volume":"12","author":"Vanhecke","year":"2010","journal-title":"Curr Cardiol Rep"},{"issue":"38","key":"10.1016\/j.jaccao.2023.12.006_bib58","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010078","article-title":"Hemodynamic profiling and prognosis in cardiac amyloidosis","volume":"16","author":"Martens","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"17-18","key":"10.1016\/j.jaccao.2023.12.006_bib60","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.cca.2011.05.007","article-title":"High-sensitive troponin T and I are related to invasive hemodynamic data and mortality in patients with left-ventricular dysfunction and precapillary pulmonary hypertension","volume":"412","author":"Eggers","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jaccao.2023.12.006_bib61","doi-asserted-by":"crossref","unstructured":"Martini N, Sinigiani G, De Michieli L, et\u00a0al. Electrocardiographic features and rhythm disorders in cardiac amyloidosis. Trends Cardiovasc Med. https:\/\/doi.org\/10.1016\/j.tcm.2023.02.006.","DOI":"10.1016\/j.tcm.2023.02.006"},{"issue":"7","key":"10.1016\/j.jaccao.2023.12.006_bib62","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13506129.2022.2060073","article-title":"Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis","volume":"29","author":"Cappelli","year":"2022","journal-title":"Amyloid"},{"issue":"12","key":"10.1016\/j.jaccao.2023.12.006_bib64","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.amjmed.2022.06.005","article-title":"Structural cardiac abnormalities in patients with atrial fibrillation\/flutter and myocardial injury","volume":"135","author":"De Michieli","year":"2022","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10.1016\/j.jaccao.2023.12.006_bib66","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib67","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ehjci\/jez180","article-title":"Diagnostic score of cardiac involvement in AL amyloidosis","volume":"21","author":"Nicol","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.jaccao.2023.12.006_bib68","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.21037\/jtd.2018.07.56","article-title":"Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function","volume":"10","author":"Hu","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis: diagnostic utility of hs-cTnT in cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10.1016\/j.jaccao.2023.12.006_bib70","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood"},{"issue":"9371","key":"10.1016\/j.jaccao.2023.12.006_bib71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jaccao.2023.12.006_bib72","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro\u2013brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jaccao.2023.12.006_bib73","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.jaccao.2023.12.006_bib74","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib75","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib77","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.jaccao.2023.12.006_bib79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.18.01398","article-title":"Validation of Mayo Clinic staging system for light chain amyloidosis with high-sensitivity troponin","volume":"37","author":"Kumar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.jaccao.2023.12.006_bib80","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib81","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.24001","article-title":"Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T: sST2 in AL Amyloidosis","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.12.006_bib82","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib83","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00392-019-01559-y","article-title":"A\u00a0novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis","volume":"109","author":"Kreusser","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib84","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jcmg.2014.03.002","article-title":"Noninvasive risk stratification of patients with transthyretin amyloidosis","volume":"7","author":"Kristen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"issue":"10","key":"10.1016\/j.jaccao.2023.12.006_bib85","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.jaccao.2023.12.006_bib86","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib87","first-page":"424","article-title":"Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems","volume":"36","author":"Cappelli","year":"2020","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.jaccao.2023.12.006_bib88","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/ehf2.13847","article-title":"A\u00a0simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"9","author":"Nakashima","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"36","key":"10.1016\/j.jaccao.2023.12.006_bib89","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib90","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1161\/CIRCULATIONAHA.107.185266","article-title":"National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure","volume":"116","author":"Apple","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jaccao.2023.12.006_bib91","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.12.006_bib92","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","article-title":"Prognostic restaging after treatment initiation in patients with AL amyloidosis","volume":"5","author":"Abdallah","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib93","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-019-0400-5","article-title":"Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis","volume":"33","author":"Hwa","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jaccao.2023.12.006_bib94","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jaccao.2023.12.006_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jaccao.2023.12.006_bib96","first-page":"4868","article-title":"Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.jaccao.2023.12.006_bib97","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jaccao.2023.12.006_bib98","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-022-01599-w","article-title":"An N-glycosylation hotspot in immunoglobulin \u03ba light chains is associated with AL amyloidosis","volume":"36","author":"Nevone","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jaccao.2023.12.006_bib99","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11897-022-00570-1","article-title":"Update on disease-specific biomarkers in transthyretin cardiac amyloidosis","volume":"19","author":"Hood","year":"2022","journal-title":"Curr Heart Fail Rep"},{"issue":"21","key":"10.1016\/j.jaccao.2023.12.006_bib100","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2016.08.066","article-title":"Troponin testing for clinicians","volume":"68","author":"Brush","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732400005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732400005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:57:39Z","timestamp":1762973859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608732400005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S266608732400005X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.12.006","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Troponin in Patients With Light\u00a0Chain and Transthyretin Cardiac\u00a0Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}